Company Overview - 4D Molecular Therapeutics (4DMT) is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics that aim to transform treatment paradigms and provide significant benefits to patients [3] - The lead product candidate, 4D-150, is designed for the treatment of blinding retinal vascular diseases, offering multi-year sustained delivery of anti-VEGF through a single intravitreal injection, thereby reducing treatment burden [3] - 4D-150 is currently in Phase 3 development for wet age-related macular degeneration and is also being studied for diabetic macular edema [3] - The second product candidate, 4D-710, is the first genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery [3] Upcoming Events - Management will participate in panel discussions at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025 [1] - Two panels will be featured: "In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications" at 9:30 a.m. ET and "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" at 2:00 p.m. ET [2] - Archived webcasts of the panels will be available for up to one year on the 4DMT website [2]

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Aspira Women's Health Inc. (OTCQX: AWHL), an AI enhanced bio-analytical based women's health company, has qualified to trade on the OTCQX® Best Market. Aspira Women's Health Inc. upgraded to OTCQX from the OTCQB® Venture Market. Aspira Women's Health Inc. begins trading today on OTCQX under the symbol “AWHL.” U.S. investors can ...

Core Insights - INmune Bio, Inc. is participating in the Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22-23, 2025, where CEO David Moss will discuss the company's CORDStrom™ platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) [1][2] Company Overview - INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases [3] - The company has three product platforms: - Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which neutralizes soluble TNF to address immune dysfunction [3] - CORDStrom™, a proprietary platform using human umbilical cord-derived mesenchymal Stromal/Stem cells, which has completed a blinded randomized trial for RDEB [3] - INKmune®, designed to enhance natural killer cells to eliminate minimal residual disease in cancer patients, currently in trials for metastatic castration-resistant prostate cancer [3] Event Details - The Maxim Growth Summit will be held at the Hard Rock Hotel in New York City, with David Moss available for one-on-one meetings throughout the conference [1][2]

Core Viewpoint - Hong Kong Exchanges and Clearing (HKEX) is set to launch the Hang Seng Biotech Index Futures on November 28, aimed at providing a risk management tool for investors interested in the rapidly growing biopharmaceutical sector in mainland China [1][3]. Group 1: Product Details - The Hang Seng Biotech Index Futures will be based on the Hang Seng Biotech Index, tracking the performance of the 30 largest Hong Kong-listed Chinese pharmaceutical and medical device companies [2]. - The futures will trade under the code HBI, with a contract multiplier of HK$50 (approximately US$6.40) per index point [5]. Group 2: Market Impact - The introduction of this futures product is part of HKEX's strategy to enhance Hong Kong's status as Asia's leading derivatives trading and risk management center, catering to the evolving needs of global investors [3][4]. - The new futures contracts are expected to increase market liquidity by attracting more institutional investors to participate in equity trading [6]. Group 3: Regulatory Aspects - The Securities and Futures Commission will waive the transaction levy for the first six months of trading for the new contracts, with margin rates to be announced later [6].

Core Insights - U.S. biotech firm Nabla Bio has entered into a second significant research partnership with Japanese drugmaker Takeda Pharmaceutical, focusing on the application of artificial intelligence to enhance drug development processes [1] Group 1: Partnership Details - The collaboration aims to deepen the integration of artificial intelligence in research and development efforts [1] - This partnership follows a previous agreement, indicating a strong commitment from both companies to leverage AI technologies [1] Group 2: Industry Implications - The partnership reflects a growing trend in the biotech industry where companies are increasingly utilizing AI to accelerate drug discovery and development [1] - Such collaborations may lead to more efficient processes and potentially faster time-to-market for new therapeutics [1]

Core Insights - Nabla Bio has announced a multi-year research collaboration with Takeda, focusing on de novo therapeutics design using generative AI [1] - The agreement includes upfront and research cost payments in the double-digit millions and potential success-based payments exceeding $1 billion [1] - The collaboration will utilize Nabla Bio's proprietary biomolecular design platform, Join [1]

Core Insights - Biotech stocks experienced a significant after-hours rally, with SOPHiA GENETICS and SELLAS Life Sciences leading the gains due to positive announcements regarding upcoming data presentations [1][2]. Company Highlights - SOPHiA GENETICS (SOPH) saw its shares increase by nearly 10%, closing at $4.44 [3]. - SELLAS Life Sciences Group Inc. (SLS) shares rose by 3.5% to $2.07 after announcing the presentation of preclinical efficacy data for its CDK9 inhibitor, SLS009, at the ESMO Congress 2025 [2]. - Other notable biotech companies that experienced stock price increases include Ironwood Pharmaceuticals (up 6.76% at $1.58), Spectral AI (up 8.60% at $2.40), and Adverum Biotechnologies (up 7.21% at $4.46) [3].

Core Viewpoint - Spyre Therapeutics, Inc. has announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, aiming to raise approximately $275.0 million in gross proceeds before expenses [1][2]. Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing advanced treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [5]. Offering Details - The public offering is expected to close around October 15, 2025, pending customary closing conditions [2]. - The underwriters have an option to purchase an additional 2,229,729 shares at the public offering price [1]. - Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are the joint book-running managers for the offering [2]. Regulatory Information - A registration statement related to the offering has been filed with the SEC and became effective on March 7, 2025 [3]. - The offering will be conducted through a prospectus supplement and accompanying prospectus [3].

Core Insights - Proactive is a financial news and online broadcast organization that provides fast, accessible, and actionable business and finance news to a global investment audience [2][3] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's editorial and broadcast operations are managed by a seasoned team, ensuring quality control and content production across multiple global locations [1][2] Company Operations - Proactive operates with a team of experienced news journalists across key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - The organization produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - Proactive employs both human content creators and technology to enhance workflows, ensuring a blend of expertise and innovation in content production [4][5] Market Focus - The company delivers news and insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive's content is designed to engage and excite motivated private investors, reflecting a commitment to providing valuable market insights [3]

Core Insights - Protagonist Therapeutics, Inc. (PGTX) has gained attention recently, particularly due to interest from Johnson & Johnson (JNJ) [1] Company Overview - Protagonist Therapeutics is focused on innovative biotechnology, emphasizing unique mechanisms of action and first-in-class therapies [1] - The company aims to reshape treatment paradigms through platform technologies [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis [1] - The analyst has been active in the investing space for five years, with a focus on biotech equity analysis for the last four years [1] Research Focus - The research approach combines scientific expertise with financial and market analysis to evaluate drug candidates, competitive landscapes, clinical trial designs, and market opportunities [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector [1]